• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Sunday, August 2, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Two Popular IV Fluids Show Equal Effectiveness in Treating Pediatric Septic Shock

Bioengineer by Bioengineer
June 5, 2026
in Health
Reading Time: 3 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

In a landmark international clinical trial spanning five countries and involving 47 pediatric emergency departments, researchers have delivered a definitive verdict on the safety and efficacy of intravenous fluid treatments for septic shock in children. Conducted at prestigious institutions including Ann & Robert H. Lurie Children’s Hospital in Chicago, the study rigorously compared the outcomes of balanced crystalloid fluids, which closely emulate the body’s natural plasma composition, against the traditional 0.9% saline solution. The conclusive results, published in the New England Journal of Medicine, reveal no significant difference in patient outcomes between the two commonly used IV fluids for pediatric septic shock resuscitation.

Septic shock represents one of the most critical emergencies in pediatric medicine, characterized by a dysregulated, severe systemic response to infection that precipitates multiple organ failure. The cornerstone of initial treatment involves rapid administration of intravenous fluids to restore hemodynamic stability and preserve organ function. Historically, the selection of IV fluids—balanced crystalloid versus normal saline—has been a subject of debate linked to potential impacts on renal outcomes and acid-base homeostasis. While balanced fluids mimic the electrolyte composition of plasma and possess buffering capacity, normal saline contains higher chloride content and has been postulated to exacerbate kidney injury under certain conditions.

Previous smaller-scale investigations yielded inconsistent findings on whether balanced crystalloids confer renal protective advantages, complicating the establishment of clear clinical guidelines. This ambitious multicenter trial enrolled over 9,000 pediatric patients ranging from 2 months to less than 18 years old, all presenting with suspected septic shock. The sheer sample size, diversity of participants, and emergency department settings provided a robust framework to assess real-world effectiveness and safety across varying healthcare environments.

The lead investigators employed a pragmatic, randomized controlled design, recognizing the critical need for rapid interventions in emergent situations. Due to the acute nature of septic shock, obtaining traditional informed consent prior to enrollment was impractical. Instead, the study innovatively integrated community engagement strategies to address ethical considerations. Stakeholders including families of children with heightened sepsis risk—such as oncology patients and immunocompromised individuals—participated in focus groups. Institutional advisory boards collaborated extensively, ensuring transparency and incorporating feedback to optimize study protocols and family understanding.

Dr. Elizabeth Alpern, the study’s co-author and Division Head of Emergency Medicine at Lurie Children’s, emphasized the importance of this comprehensive approach: “We engaged parents, patients, and the community early and continuously to ensure their voices shaped the research.” She further articulated that the findings effectively end the uncertainty surrounding fluid choice in pediatric septic shock resuscitation, enabling clinicians worldwide to make fluid selections guided by availability and logistical factors without compromising patient safety or efficacy.

Core outcomes measured included major adverse kidney events within 30 days and persistent kidney dysfunction, critical indicators given the kidney’s vulnerability during sepsis and fluid resuscitation. The equivalence of balanced crystalloids and normal saline in these parameters is especially pertinent, given prior concerns about saline-induced hyperchloremic acidosis and potential nephrotoxicity. The study’s statistical rigor and patient-centered outcome focus reinforce the robustness of these conclusions.

The trial’s findings have profound implications beyond immediate fluid choice. They redirect clinical and research focus toward novel, more promising avenues for enhancing pediatric sepsis care rather than lingering on fluid controversies. Innovative therapies, biomarker-guided interventions, and personalized treatment algorithms may now take center stage, supported by the assurance that initial resuscitation fluid choice is flexible yet safe.

Beyond the immediate clinical insights, this study also exemplifies how large-scale, ethically conducted emergency medicine research can be achieved in pediatrics. By employing adaptive community consultation and embracing diverse institutional participation, the trial sets a precedent for future investigations requiring rapid enrollments in critical care settings without sacrificing patient rights or scientific integrity.

Ann & Robert H. Lurie Children’s Hospital of Chicago, as a leading independent pediatric research institution, played a central role in orchestrating and executing this complex multicenter study. Their Grainger Research Program in Pediatric Emergency Medicine continues to drive pioneering clinical research aimed at transforming acute pediatric care and improving outcomes for vulnerable children nationwide and internationally.

In summary, the extensive, high-quality evidence generated by this international randomized clinical trial decisively confirms that both balanced crystalloid and 0.9% saline intravenous fluids are equally safe and effective for resuscitating children with septic shock. This decision empowers clinicians globally to tailor fluid therapy to local resources, logistical considerations, and institutional protocols without compromising patient safety. The study also underscores the importance of community involvement in emergent clinical research and provides a clear path forward for innovation in pediatric sepsis treatment.

Subject of Research: Pediatric septic shock fluid resuscitation
Article Title: (Not explicitly provided)
News Publication Date: (Not explicitly provided)
Web References: https://www.nejm.org/doi/full/10.1056/NEJMoa2601969
References: New England Journal of Medicine DOI: 10.1056/NEJMoa260196
Image Credits: (Not provided)
Keywords: Sepsis, Pediatric Emergency Medicine, Septic Shock, Intravenous Fluids, Balanced Crystalloid, Saline, Kidney Outcomes, Clinical Trial, Pediatric Intensive Care, Fluid Resuscitation

Tags: acid-base balance in septic shockbalanced crystalloid fluids vs salinefluid choice impact on kidney functionintravenous fluid composition comparisonintravenous fluid therapy in childrenIV fluid safety in pediatricsmulti-country clinical trial pediatric sepsisoutcomes in pediatric septic shockpediatric critical care fluid managementPediatric Emergency Medicinepediatric septic shock treatmentseptic shock resuscitation protocols

Share12Tweet8Share2ShareShareShare2

Related Posts

Dietary Diversity Linked to Frailty and Prefrailty in Japan’s Hisayama Population

August 1, 2026
Machine Learning Imaging Predicts Parkinson’s Genotype, Mitochondrial-Lysosomal Abnormalities in iPS Neurons

Machine Learning Imaging Predicts Parkinson’s Genotype, Mitochondrial-Lysosomal Abnormalities in iPS Neurons

August 1, 2026

Cognitive and Physical Disabilities Shape Depression Risk, Recovery in Older Chinese Adults

August 1, 2026

Randomized Trial Tests Losartan and Prednisolone for Post-COVID Syndrome and Cardiac Inflammation

August 1, 2026

POPULAR NEWS

  • KAIST develops treatment targeting cancer cachexia, a debilitating wasting syndrome

    29 shares
    Share 12 Tweet 7
  • What Long-Term Evidence Reveals About Hypoglycemia in Late-Preterm Infants

    29 shares
    Share 12 Tweet 7
  • Dietary Diversity Linked to Frailty and Prefrailty in Japan’s Hisayama Population

    29 shares
    Share 12 Tweet 7
  • Machine Learning Imaging Predicts Parkinson’s Genotype, Mitochondrial-Lysosomal Abnormalities in iPS Neurons

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

KAIST develops treatment targeting cancer cachexia, a debilitating wasting syndrome

What Long-Term Evidence Reveals About Hypoglycemia in Late-Preterm Infants

Dietary Diversity Linked to Frailty and Prefrailty in Japan’s Hisayama Population

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 85 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.